Research chemicalResearch chemicalPhenethylaminePsychedelic
Allylescaline
Also known as AL · 3-allyloxy-4,5-dimethoxyphenethylamine
Allylescaline (AL) is the 3-allyloxy analogue of mescaline, a synthetic scaline psychedelic from PiHKAL. It is potent, visually strong and long-acting, and has circulated as a grey-market research chemical with little formal human study.
01 Overview
Allylescaline places an allyloxy group at the 3 position of mescaline. Reports describe vivid, colourful visuals with a euphoric and emotionally engaging character over an 8-12 hour course.
Human evidence is anecdotal, drawn from self-experiments and grey-market use. Its safety profile is not established.
02 Mechanism
Agonist at serotonin 5-HT2A receptors; the allyloxy substitution raises potency relative to mescaline.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 10–20 mg | Oral | |
| Common | 20–45 mg | Oral | PiHKAL range. |
| Strong | 45–70 mg | Oral |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Strong visual enhancementVivid colour and geometry, often reported as more visual than mescaline. | Anecdotal | ||
| EuphoriaReported mood lift and emotional engagement. | Anecdotal | ||
| Long durationFull-day experience. | 8-12 h | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| NauseaOnset queasiness. | Mild | Common | Anecdotal | |
| Sympathomimetic stimulationPresumed cardiovascular stimulation. | Mild | Common | Unconfirmed | |
| AnxietyAnxiety at higher doses. | Moderate | Dose-dependent | Anecdotal |
06 Legal status
United Kingdom
Class A
as of Jan 2026
United States
Unscheduled
Possible Analogue Act coverage. · as of Jan 2026
07 References
PiHKAL: A Chemical Love Story (Allylescaline entry)Shulgin A. & Shulgin A., 1991
08 Discussion0 comments
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.